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SUMMARY: Murine models are the most commonly used and best investigated among the animal
models of HGG. They constitute an important weapon in the development and testing of new
anticancer drugs and have long been used in preclinical trials. Neuroimaging methods, particularly MR
imaging, offer important advantages for the evaluation of treatment response: shorter and more
reliable treatment end points and insight on tumor biology and physiology through the use of functional
imaging DWI, PWI, BOLD, and MR spectroscopy. This functional information has been progressively
consolidated as a surrogate marker of tumor biology and genetics and may play a pivotal role in the
assessment of specifically targeted drugs, both in clinical and preclinical trials. The purpose of this
Research Perspectives was to compile, summarize, and critically assess the available information on
the neuroimaging features of different murine models of HGGs, and explain how these correlate with
human disease and reflect tumor biology.
ABBREVIATIONS: AIF  arterial input function; ATP  adenosine triphosphate; BOLD  blood
oxygen level—dependent; DCE  dynamic contrast-enhanced; DSC  dynamic susceptibility
contrast; FLASH  fast low-angle shot; gadolinium-DTPA  gadolinium-diethylene-triamine penta-
acetic acid; GEMM  genetically engineered mouse model; GRE  gradient recalled-echo; HGG 
high-grade glioma; MMP2  matrix metalloproteinase type 2; MVD  mean vascular density;
rCBV relative cerebral blood volume; VEGF  vascular endothelial growth factor
Animal models of HGG have become an imperative tool inthe development and testing of new anticancer drugs. The
combination of these advanced neuroimaging methods pro-
vides a novel integrated environment in which a collection of
noninvasive biomarkers validated on well-defined animal
models may provide important clues to tumor biology and
response to treatment, with potential applications in human
neoplasms. In general, the use of animal models overcomes
many of the limitations found in the clinical setting, including
impracticable serial tissue sampling and difficulties in estab-
lishing correlations between tumor physiopathology and its
genetic profile, a circumstance limiting considerably the suc-
cessful implementation of tailored personalized cancer
treatments.
Among neuroimaging methods, MR imaging is the most
common technique to assist the management of patients with
brain tumors; it is free of ionizing radiation, overall well-tol-
erated, and provides detailed anatomic and functional infor-
mation. Neuroimaging features of murine models of HGG
have been less explored due to technical limitations. High-
resolution MR imaging of small animals requires high-field
magnets with small bores and dedicated coils, adequate anes-
thesia, and tailored fixation devices (Fig 1).
Murines are the most commonly used and are the best
investigatedmodels of human glioma. They are easy to handle,
have a short life span, and develop central nervous system
tumors that are similar to their human counterparts.1,2 More-
over, the genetic information currently available on theMouse
Genome Project and the technologic developments in genetic
manipulation (transgenics, knockouts, and conditional
knockouts) make this model very appealing for unraveling
HGG biology.2
This article provides an overview of the currently available
murine models of HGG and of the wide gamut of neuroimag-
ing methodologies that can be used to characterize their mor-
phology, physiology, and biology.Wewill specifically focus on
MR imaging, emphasizing conventional and functional tech-
niques and their potential applications in clinical and preclin-
ical trials.
Murine Models of HGG
Awide range ofmurinemodels ofHGGare available, each one
having different advantages and drawbacks.1 These models
can be broadly divided into endogenous and exogenous, de-
pendingwhether the tumor originates in the primary host or is
grafted or implanted into the host. Endogenous models in-
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clude spontaneous carcinogenesis in inbred strains, carcino-
genic-induced tumors by intrauterine or postnatal exposure
to radiation, chemical or infectious mutagenic agents, and ge-
netically engineered tumor models obtained by introducing
genetic changes known to promote carcinogenesis in humans.
Exogenous models require grafting or implantation of a sus-
pension of tumor cells, tumor explants, or tumor spheroids
from primary or stable tumor cell lines into the host animal.
Whereas endogenous models more accurately reproduce and
recapitulate the biologic behavior and the complex relation-
ship between the tumor and itsmicroenvironment, grafts have
a lower cost and amore predictable and reproducible behavior
in terms of tumor take and time for tumor development,mak-
ing them more appealing for preclinical trials.2,3
Graft models may be syngeneic when the tumor and host
have the same origin (allograft) or heterogeneic when they
have different origins (xenograft). Human xenografts recapit-
ulate the human neoplasm but are not representative of the
parent tumor-host interaction because the tumor and mi-
croenvironment have different origins.4 Moreover, they re-
quire the use of nude mice, departing further from the actual
clinical situation.
According to the grafted or implanted site, models are sub-
divided into orthotopic (tumor implanted in its parent organ)
or heterotopic (tumor implanted in a different organ). Ortho-
topic models are representative of the tumor environment,
but in the brain, they are of difficult clinical access requiring
imaging to assess tumor development and growth. In most
heterotopic models, tumors are implanted in the subcutane-
ous soft tissues where clinical assessment is easy and immedi-
ate, but unfortunately they do not represent the parent tumor-
microenvironment interaction.
Tumor explants from actual patients may be implanted in
mice in the form of grafts, spheroids, or primary cell lines,
providing specific information on tumor behavior and tumor
response to different treatment regimens, serving as an invalu-
able tool for personalized oncologic management.5 Grafting
tumor fragments by microsurgical techniques avoids the arti-
ficial diffusion of intracerebral injections of cell suspen-
sions.4,5 Engraftment of primary glioblastoma biopsies has
shown high take rates but a long average latency.6 The use of
primary tissue prevents the genetic drift and phenotypic
changes secondary to prolonged passages in vitro, reproduces
the phenotypic traits of the native tumor, and displays more
cellular heterogeneity than established cell lines.6 The use of
spheroids (3D cultures), as opposed to cell suspensions (2D
cultures), avoids the disruption of the stromal compartment
preserving the original tumor environment.6
Many HGG cell lines of human andmurine origin are cur-
rently available and accurately reproduce the histologic and
cytologic features of human neoplasms.1,7,8 Cell lines of recur-
rent tumors that reproduce the aggressive behavior and treat-
ment resistance of clinical recurrences are also available.9
These can be obtained directly from a recurrent tumor; from
an enriched lungmetastasis assay, or from sorting tumor cells,
with specific markers of aggressiveness, by using fluorescence-
activated cell sorting.9 Furthermore, it is possible to isolate and
purify brain tumorinitiating cells that give rise to highly re-
sistant neoplasms.10
GEMMs recapitulate the genetic events of human neo-
plasms, provide an increased understanding of brain tumor
biology, and help the development of treatment strategies that
target specific oncogenic pathways.8,11,12 In these models, the
initiating genetic event is known; mice spontaneously develop
orthotopic tumors and are immunocompetent.12 They can be
used for screening and target validation and to evaluate the
efficacy and potential off-target effects of new drugs.12 For
limiting tumor development to local somatic cells, gene deliv-
ery systems based on viral vectors and transgenic receptors
under specific promoters (glial fibrillary acid protein to hit
astrocytes and nestin to hit glioneuronal progenitors) are now
widely available. The low transfection efficiency and the need
for secondary stochastic genetic events for tumor onset lead to
low tumor take and unpredictable tumor latency. These were
the major problems limiting the use of GEMMs in wide-scale
high-throughput preclinical trials.8,10,11,13 However, breeding
transgenicmicewith knockoutmicewith targeted deletions or
mutations in tumor-suppressor genes leads to malignant
transformation at a faster andmore predictable rate, reflecting
both the induction and progression of tumorigenesis.8,12,13
More recently, transplantable models derived from
GEMMs combine the advantages of both endogenous and ex-
ogenous models: high penetrance; rapid and predictable tu-
mor growth; use of syngeneic immunocompetent host; and
reproduction of the genetic,molecular, and histologic features
of human parental tumors.11
Fig 1. Dedicated MR imaging magnet for small animals and scanning devices. A, 7.4T Bruker Pharmascan (Bruker BioSpin, Rheinstetten, Germany) with a 160-mm horizontal bore (small
arrows). A dedicated fixation device for mice brain studies is seen in place, equipped with continuous isofluorane anesthesia (long arrow), respiratory monitoring, and a thermostatic water
mat set for 37°C (curved arrows). B, Dedicated mouse head coil (22-mm diameter). C, In-house built poly-methyl-methacrylate bed and fixation device with a Swiss mouse in place.
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In summary, a valid brain tumor model should fulfill the
following criteria: 1) derive from glial cells, 2) grow as a stable
cell line, 3) propagate in vivo by serial transplantation, 4) have
a predictable and reproducible tumor take and growth rate, 5)
maintain gliomalike features, 6) have a predictable host sur-
vival (long enough to allow the assessment of treatment ef-
fect), 7) be not or weakly immunogenic in the syngeneic host,
7) have no extent beyond the brain, and 10) have a response to
conventional treatment, or lack of it, predicting the behavior
of the human counterpart.10
The main features of the currently available mouse models
of HGG are summarized in Tables 1 and 2.
Neuroimaging Modalities Applied to Murine Models of
HGG: Why and How
Neuroimagingmethods, as applied tomousemodels of HGG,
constitute a powerful tool to guide the development, test the
efficacy, and monitor the effect of new drugs in preclinical
trials. They allow the use of smaller animal cohorts, shorten
the duration of studies (by settingmore efficient endpoints for
treatment response than survival), and provide serial longitu-
dinal information in vivo about tumor physiology and biol-
ogy.14 In short, neuroimaging is placed ideally to become a
longitudinal biomarker in clinical and preclinical testing.
Many different imagingmodalities have been proposed for
imagingmice: optical imaging (bioluminescence imaging, flu-
orescence, and near-infrared optical imaging), CT, MR imag-
ing, MR spectroscopy, SPECT, and PET, providing different
and often complementary information.15More recently, mul-
timodality imaging combines the advantages of different im-
aging modalities to get a fully integrated picture of tumor be-
havior and of neurotherapeutic effects: PET/CT, PET-MR,
fluorescent molecular tomography, MR bioluminescence im-
aging.15With the exception of optical imaging, all other imag-
ing modalities can be easily translated to human disease. Fu-
sion of these imagingmodalities allows in vivo visualization of
trifusion reporter genes labeled with different markers de-
picted by different imaging techniques.
On clinical grounds,MR imaging is used to diagnose, assess
disease extent, guide treatment decisions, evaluate response
over time, and define patient prognosis.16 Existing protocols
allow a range of both structural and functional information to
be drawn from imaging datasets: Imaging phenotypes can be
defined, quantified, and compared with the biologic and ge-
netic profiling of tumors (Fig 2).17,18
Themost important diagnostic andprognostic features of a
tumor involve its perfusion status, oxygenation, and glucose
consumption. At the present time, MR imaging can render
information on tumor burden, cell density, vascularization,
tumor oxygenation, and metabolism through the use of func-
tional sequences such as DWI, PWI, BOLD and tissue oxygen
leveldependent imaging, and MR spectroscopy. These pro-
vide high-resolution parametric mapping with an easy read-
out for treatment efficacy and longitudinal drug monitoring
(Fig 3).16 Multispectral analysis techniques can provide auto-
mated differences between viable and necrotic, highly prolif-
erative versus quiescent, highly vascularized versus poorly vas-
cularized, and hypoxic versus normoxic tumor tissue.
Therefore,MR imaging phenotypes provide indirect mapping
of gene expression and can be used to select specific tumor
regions for genomic analysis or for targeted oncotherapy. Dif-
ferent tumor phenotypes have already been identified in hu-
mans and correlated well with different patterns of gene ex-
pression: angiogenic and poorly invasive, angiogenic and
invasive, and nonangiogenic invasive phenotypes.16,19
Adapting human protocols to the mouse scale involves
many challenges: obtaining imageswith similar resolution and
signal intensity–to-noise ratios when facing a 10- to 15-fold
decrease in voxel size on each dimension, increasing image
throughput for large-scale screening, and analyzing anatomic
images and parametric data from multiple mouse datasets.16
MR imaging of mice can be performed in clinical scanners
with or without dedicated radio-frequency coils or in dedi-
cated small-bore high-field-strength scanners (now as high as
17.6T).16
Mouse imaging can be performed in vivo or postmortem
and in series (a single animal at a time) or in parallel (by scan-
ning various animals simultaneously, also known as multiple
mouse MRI, Fig 4).20
Postmortem. MR imaging provides high-resolution im-
ages by reducing unavoidable pulsatile movements, allowing
strict fixation, very long scanning times, and the use of high
concentrations of gadolinium.16 The excellent correlation
with pathology sections justifies the eponym “MR histology”
and provides in situ phenotypic information. Postmortem im-
aging can be easily added to in vivo studies at the end of the
follow-up time to guide conventional histologic analysis.With
an 11.7T MR imaging scanner and scanning times up to 37
hours, an in-plane resolution of 20 m can be achieved.16 In
the Visible Mouse Project, FSE T2-weighted images with a
100-m isotropic resolution were produced within a reason-
able timeframe (2 hours 45 minutes) (Fig 5).16,21
The power of preclinical trials increases with the increasing
number of animals, requiring an intervention and a control
group. Therefore, a high image throughput and an efficient
and standardized imaging protocol are essential if one aims to
use MR imaging end points. Imaging of single mice is expen-
sive and time-consuming and exhausts scanner availability for
research.Multiple mouseMRI overcomesmost of these prob-
lems.22 Virtually, any clinical scanner can be used without
modification, though at the cost of poor resolution and image
degradation. Alternative magnet designs have been developed
for this purpose, each with its own advantages and disadvan-
tages. Large bore, large gradient, and large radio-frequency
coilmagnets can be used to image severalmicewithin the same
FOV, but labor intensive postprocessing is required to sepa-
rate datasets of individualmice. The use of a common gradient
Table 1: Distinctive features of the 2 main groups of HGG mouse
models
Features
Endogenous models (GEMMs and nontargeted mutagenesis/carcinogenesis)
Unpredictable latency periods, growth curves, tumor location, and
morphology; implies regular screening for tumor detection and longitudinal
monitoring for progression; more physiologic and best representing human
disease
Exogenous models or xenografts
Predictable and reproducible, high tumor take; best for high throughput
preclinical trials; less physiologic and less representative of the actual
human condition
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Table 2: Main features of currently available mouse models of HHG
Animal Model/Subtype Immunogenicity
Reproducible
Tumor-Host
Interaction
Tumor Take
and Growth
Rate
Reproducibility
of Human
HGG
Genetics and
Biology
Stromal
Disruption
High-
Throughput
Preclinical
Trials
Exogenous models or xenografts
Syngeneic None/low Yes
Heterogeneic High/requires nude mice Yes
Orthotopic Yes Yes
Heterotopic No Yes
Cell suspension High Yes
Spheroids Moderate Yes
Tumor explants: Low No
From primary cell lines High Depends on
the cell line
From patient tumors Low High
Endogenous models
Carcinogenically induced
(RT, QT, viral mutagenesis)
No
GEMMs No
Transplantable GEMMs Yes
Note:—RT indicates radiation therapy; QT, chemotherapy.
Fig 2. Flow chart for integrated MR imaging, histology, and genomic and proteomic approaches in models of HGG. A, Representative Swiss mouse. B, Gadolinium-enhanced axial
T1-weighted image shows an implanted Gl261 HGG. C, Parametric T2*map of the tumor in B. D, Parametric histogram of T2* values of C. E, Isolated normal brain from a representative
Swiss mouse. F, Representative hematoxylin-eosin–stained section across a formalin-fixed paraffin-embedded mouse brain carrying an implanted HGG. Reproduced from Lal et al17 with
permission from the Journal of Neurosurgery Publishing Group. G, Microscopic view (40) of a fixed and stained section across an HGG (small black bar on the lower right corner represents
50 m) shows pseudopalisading necrosis characteristic of HGG. Reproduced from Collier et al18 with permission from the American Association for Cancer Research. H, Gene-expression
profiling (RT qPCR results) from a representative Gl261 HGG. I, Representative VEGF-A protein expression as detected by Western blot analysis.
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coil and individual radio-frequency coils for each mouse al-
lows smaller FOVs but requires appropriate shielding to iso-
late individual coils (Fig 6). Postprocessing is labor-intensive,
requiring individual reconstruction of each separate dataset
and FOV unwrapping due to phase-encoding aliasing in off-
center samples. Streamlining of scout views and simultaneous
ROI selection for functional studies constitute additional
problems. Acquisition of 3D isotropic images with retrospec-
tive ROI selection is preferred in these circumstances. The use
of short TR sequences is also limited because to maintain im-
age resolution, one must increase the duration of gradient
pulses. To facilitate data analysis of multiple mouse MRI,
coregistration, automated analysis, and image-segmentation
packages are now available.
TheuseofMRspectroscopy inmice is evenmore challenging,
requiring very small volumes of interest and custom high-order
shim coils. Therefore, well-resolved spectra are difficult to obtain
due to size and time constraints. Metabolic phenotyping can,
however, be obtained ex vivo in pathologic specimens through
the use of high-resolutionmagic angle spin spectroscopy.23
MR Imaging Characterization of Mouse Models of HGG
AMEDLINE search by using the search engines PubMed, Sco-
pus, and Index Medicus and search terms “murine models of
Fig 3. Serial axial T2-weighted (A) and contrast-enhanced T1-weighted (B) images of a Gl261 C57/Bl6 mouse model of HGG, showing tumor growth and increased enhancement over a
period of 4 weeks. C, ROIs delineating the tumor (green limit) 1, 2, and 4 weeks after implantation; and nonlinear fitting (red) of signal intensity versus TE (blue) in representative pixel
and parametric T2* maps depicting T2* values in the selected ROI. D, T2* histograms nicely depict the temporal variation of T2* values with tumor progression modified by small differences
in oxygen blood saturation reflected by the paramagnetic effect of deoxyhemoglobin.
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HGG,” “neuroimaging features,” “MR imaging features,” and
“MR imaging in preclinical trials” retrieved 50 studies, criti-
cally summarized below. MR imagingbased studies in-
cluded conventional MR images either isolated or as part of a
multimodality imaging approach, functional imaging (PWI,
DWI and BOLD), andMR imaging applied in preclinical trials
by using murine models of HGG.
Conventional MR imaging
In most of these studies, serial MR imaging was used to screen
and monitor tumor growth, to characterize the imaging fea-
tures of different models of HGG, and to correlate imaging
phenotypes with tumor histology and gene expression to de-
termine their predictive range (On-line Table 1).24-32 In mu-
rines, symptoms associated with tumor development are in-
distinguishable from those secondary to hydrocephalus.
Therefore, imaging is mandatory to accurately screen for in-
tracranial tumors.
The MR imaging features of the U87MG and U251 xeno-
grafts were characterized by Radaelli et al.25 These authors
found a good correlation between the area of necrotic tumor
and the intensity of gadolinium enhancement determined on
serial MR imaging studies and quantitative scores of percent-
age necrosis andMVD found on histopathology.U251 tumors
featured HGGs resembling the human counterpart (with ill-
defined infiltrating margins, necrosis, and surrounding
Fig 4. A, Multiple mouse parallel imaging. Coronal (left) and sagittal (right) sections from FSE multiple mouse MRI images of 4 mice (numbered 1– 4). Each 3D image has a 100-m isotropic
resolution. Scan duration was 2 hours 50 minutes. Reproduced from Nieman et al16 with permission from John Wiley and Sons. B, Multiple mouse MRI of GEMMs of HGG T2-weighted
(1), T1-weighted (2), and gadolinium-enhanced T1-weighted (3) images, obtained on a 1.5T Signa clinical scanner (GE Healthcare, Milwaukee, Wisconsin) by using a common receiver coil,
clearly demonstrates which mice developed brain tumors (white arrows) and differentiates brain tumors from hydrocephalus. Reproduced from Koutcher et al with the authors’ permission.26
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edema), whereas U87MG neoplasms were mostly rounded,
well-demarcated from the surrounding brain, and closer to
metastatic disease than to an aggressive primary brain tumor.
However, strong gadolinium enhancement, featuring intense
neoangiogenesis, makes this tumor model ideal to evaluate
response to antiangiogenic drugs.
Koutcher et al26 used multiple mouse MRI for screening
GEMMs of HGG by using a clinical 1.5TMR imaging scanner
and an 86-cm solenoid coil. MR imaging studies demon-
strated a 20%–30% tumor take and a strong correlation be-
tween contrast enhancement and the presence of glomeruloid
microvascular proliferation assessed on histology. Despite the
low resolution, MR imaging was sensitive enough for tumor
screening by using T1-weighted, T2-weighted, and contrast-
enhanced T1-weighted signal-intensity ratios between tumor
and normal brain. Size-limit detection was 0.8 mm with 5
false-negatives below 1 mm.
Various multimodality imaging studies included MR im-
aging to characterize HGG tumor models and to appraise
treatment response.
The DBT orthotopic xenograft of HGG was featured by
Jost et al24 by using a multimodality imaging approach
which comprised MR imaging, PET, and optical imaging.
Good correlation was found between tumor volumes deter-
mined on MR imaging studies and on the pathology speci-
men both in control and carmustine treatment groups
given 1 or 2 carmustine doses, respectively. Tumor-growth
curves and growth-rate exponents showed a 7-day delay of
tumor growth burst in the single carmustine dose group
and an 18-day delay on the 2-dose group, after which tu-
Fig 5. The visible mouse project (3D MR imaging of a whole fixed C57Bl/6J mouse). Images acquired with an isotropic array with a 256  256  1024 matrix and 110  110  110
m in-plane resolution. Coronal (top) and representative axial T1-weighted sections from the brain (left), thorax (center), and abdomen (right). Reproduced from Johnson et al21 with
permission from the Radiologic Society of North America.
Fig 6. Multiple mouse MRI loading system described by Dazai et al.22 Mice loading array equipped with anesthesia and a mouse hive, which holds up to 19 receiver coils. Reproduced
from Dazai et al22 with permission from John Wiley and Sons.
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mors returned to baseline growth rates approaching those
of nontreated controls.
MR multispectral tissue segmentation was performed by
Gordon et al27 in HJC-15c orthtotopic xenografts, by using a
1.5T clinical scanner and a conventional wrist coil, to discrim-
inate tumor boundaries and different tumor components. Au-
tomated multispectral segmentation analysis, by using input
from 3 different 3D volumetric acquisitions (GRE, inversion
recovery-GRE, and steady-state free precession) was able to
discriminate tumor from normal brain, edema, and CSF and
to separate different components of these heterogeneous tu-
mors (necrotic from viable, enhancing from nonenhancing
tumor) with higher reproducibility and better histologic cor-
relation and in a shorter time than manual delineation based
on visual assessment.
The influence of tumor models on the evaluation of drug
efficacy on preclinical trials was demonstrated by Kemper et
al.28 Several FVB xenografts known to grow behind an intact
BBB (Mel 57, K173 Br2, and RG2) and to disrupt the BBB
(U87MG and Mel57 transfected with VEGF-A) were imaged
by MR and bioluminescence imaging. The intensity of con-
trast enhancement,measured on a dynamic GRET1-weighted
sequence after IV administration of gadolinium-DTPA, was
positively correlated with MVD and immunohistochemistry
for Ki67 (a proliferation marker) and glucose transporter 1 (a
BBB marker absent in leaky vessels lacking a functional BBB).
Not surprisingly, treatment efficacy of a 4-week course of oral
temozolomidewas higher inmodels with BBB disruption, fea-
turing leakier vessels and more intense contrast enhancement
(U87MG) than inmodels growing essentially behind an intact
BBB with poor contrast enhancement. Whereas the former
may overestimate, the latter may underestimate treatment
response.
MR imaging coupled with diffuse optical fluorescence to-
mography was attempted by Davis et al29 to analyze tumor
metabolism in a U-251 orthotopic xenograft. Authors were
able to assess and visualize themetabolic activity of this tumor
model in vivo by measuring and spatially localizing the fluo-
rescence emitted by protoporphyrin IX (an endogenous
fluorophore).
To validate bioluminescence imaging and MR imaging as
quantitative tools to assess the efficacy of cytotoxic drugs, Re-
hemtulla et al30 quantified tumor volumes and log cell kill in a
9L orthotopic xenograft transfected with luciferase, both in
control and carmustine treatment groups, by using histology
as the criterion standard. Bioluminescence imaging slightly
overestimated tumor size due to scatter of emitted photons,
whereas MR imaging underestimated log cell kill because it
measures both living and dead cells, cell debris, peritumoral
edema, and infiltrating host cells as part of tumor volume,
underscoring treatment effect. Besides the lower cost, shorter
scanning times, high throughput, andminimal postprocessing
requirements, bioluminescence imaging proved to be a better
surrogatemarker of active tumor volume because light output
is only seen in metabolically active cells and does not account
for necrotic tissue. Hence, bioluminescence imaging is a very
good candidate for screening animals before more accurate,
expensive, and time-consumingmodalities, such asMR imag-
ing or PET, are undertaken to provide spatial and or func-
tional information.
Finally, Szentirmai et al,31 comparedMR imaging and bio-
luminescence imaging in the evaluation of tumor-growth ki-
netics under antiangiogenic treatment in a U87MG luciferase
transfected orthotopic xenograft. Because antiangiogenic
treatments increase the fraction of hypoxic tumor cells, at least
temporarily, and luciferase activity requires oxidation of the
substrate (luciferin), bioluminescence imaging was shown to
underestimate tumor volumes and overestimate treatment
response.
Functional MR Imaging
Perfusion MR Imaging. Tumor blood volume is a very
important biometric imaging target. Many studies have
emerged in recent years attempting to validate MR imaging–
based perfusion imaging as a biomarker of angiogenesis (On-
line Table 2).33-41 MR imaging can provide information on
tumor perfusion by tracking a bolus of an exogenously admin-
istered contrast agent or by tracking endogenousmagnetically
labeled flowing blood. The former includes DCE PWI, which
measures the T1 shortening effect of the contrast agent, and
DSC PWI, which measures the susceptibility effect of the con-
trast agent on T2* GRE images. The latter, known as arterial
spin-labeling, measures signal-intensity differences between
images obtained with and without a tagging pulse, which may
be intermittent or continuous (pulsed arterial spin-labeling or
continuous arterial spin-labeling). This technique is free of
recirculation or residual tracer effects, does not require mon-
itoring of tracer concentration time curves during the first
passage, and, being completely noninvasive, may be repeated
as often as required.
DCE-MRperfusion can be performed by using either small
molecule contrast agents that escape the disrupted BBB in tu-
mors and extravasate to the extracellular and extravascular
space or macromolecular contrast agents that remain longer
in the intravascular compartment.33,34 To minimize the effect
of extravasated contrast in perfusionmeasurements, onemust
use an AIF to measure the rate of incoming blood in a nearby
supplying artery or a pre-bolus injection. With a 3D equilib-
rium water-exchange model, it is possible to derive informa-
tion on tumor blood volume; extravascular space vascular per-
meability, and Ktrans.33,34
Perfusion parameters of the U87MG rat xenograft were
characterized by Li et al33 by using DCE-PWI after the IV
administration of 50 mol/Kg of Omniscan (gadodiamide;
Nycomed Amersham, Oslo, Norway). Using an AIF derived
from the superior sagittal sinus (a technique previously vali-
dated in rats42), the authors were able to estimate CBV, CBF,
Ktrans, and vascular permeability from first-passage T1-
weighted DCE-PWI despite extensive extravasation of the
contrast agent. However, in the absence of a criterion stan-
dard, the absolute accuracy of DCE-PWI is difficult to ascer-
tain and is highly dependent on the accurate measurement of
the AIF, quite difficult in the rat brain.
Adzamli et al34 compared different perfusion parameters
and the delineation of abnormal vascular beds among 3 differ-
ent albumin-binding contrast agents (MP-2269, MS-325, and
gadoversetamide (OptiMARK; Mallinckrodt, St. Louis, Mis-
souri) in the DBT mouse xenograft. Signal intensity was plot-
ted with time and time-to-peak; plateau and washout time
were compared withMVD and vascularmorphology, assessed
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on histology. All contrast agents showed increased blood per-
sistence compared with unbound agents (2.5 hours versus 10
minutes) anddifferent kinetics of tumor uptake and clearance.
The effect of antiangiogenic drugs in different models of
brain vascularization both in vitro and in vivo was assessed by
Goldbrunner et al.35 These authors found increased expres-
sion of angiogenic molecules in spheroids compared with cell
suspensions, which increasedwith the increasing size of spher-
oids reflecting the importance of the tumor-stroma cross-talk
and the paracrine actions of angiogenic growth factors. The
increased expression of integrin 53 in glioma endothelial
cells can be imaged by tagging a monoclonal antibody against
this protein with a paramagnetic contrast agent used as a
marker for tumor angiogenesis (Gad-LM609-Ab anti-53).43
Perfusion imaging through endogenous labeling has also
been explored in mouse models of HGG. Sun et al36 evaluated
the performance of continuous arterial spin-labeling assessing
perfusion of the U87MGmouse xenograft. Extracted imaging
parameters, CBF indexes, and apparent T1 of the tumor core,
tumor periphery, and normal brain positively correlated with
radial histologic analysis of MVD. Progressive CBF decrease
was noted from normal brain to tumor core and nicely corre-
lated with the presence of nonfunctional morphologically ab-
normal intratumoral vessels with increased resistance and
high permeability, which do not participate in effectivemicro-
circulation. The technique proved to be highly reproducible
with low inter- and intraindividual variation.
The temporal correlation between DCE-PWI and tumor
angiogenesis was appraised by Veeravagu et al37 and con-
fronted with MVD and genetic expression of VEGF and an-
giotensin 1 and 2 assessed by real-time quantitative polymer-
ase chain reaction. DCE-PWI studies were performed in the
GL261 C57Bl/6 orthotopic xenograft after the administration
of 0.1 mmol/Kg of Magnevist (gadopentetate dimeglumine;
Schering, Berlin, Germany). A stepwise increase in time-to-
peak preceded tumor growth burst and coincided with an in-
crease in MVD, vessel caliber, and increased expression of
VEGF and angiotensin 2, responsible for endothelial sprout-
ing and increased vascular leakiness. The decrease in signal-
intensity/time ratios immediately following exponential tu-
mor growth concurred with vessel normalization and
decreased leakiness and with the overexpression of angioten-
sin 1, responsible for the maturation and stabilization of new
blood vessels. Therefore, DCE-MR imaging reflects the func-
tional and architectural status of growing blood vessels in vivo,
being able to depict the angiogenic switch preceding rapid
tumor growth and the normalization of the vascular support
responsible for the infiltrating pattern of tumor growth be-
hind an intact BBB.
Using DSC-PWI, Cha et al38 correlated rCBV with MVD
andCD31 immunohistochemical staining andmaximumvas-
cular permeability with Evans blue extravasation in the Gl261
C57Bl/6 mouse xenograft. A single-section GRE T2* FLASH
sequence after the IV administration of 0.1 mmol/Kg of
Magnevist was performed, showing enhancement and in-
creased rCBV at all stages of tumor progression, with regional
and temporal differences. rCBV increased at the tumor pe-
riphery up to the first couple of weeks, reflecting the co-option
and dilation of host vessels, decreased during the second and
third weeks due to exponential tumor growth and host vessel
insufficiency, and increased again on the fourth week second-
ary to frank tumor neovascularization at the tumor margins
and surrounding centrally necrotic areas, lacking a functional
BBB.
Gossmann et al39 evaluated the role of DCEMR imaging as
a surrogatemarker of tumor response to anti-VEGFmonoclo-
nal antibody (A4.6.1) in a U87MG rat xenograft. High-reso-
lution spoiled gradient-recalled echo T1-weighted images
were obtained at different timings after a bolus injection of 0.1
mmol/Kg of Magnevist, to extract enhancing tumor volumes
and perfusion parameters. A statistically significant decrease
in tumor volume, fractional plasma volume, and endothelial
transfer coefficient was found between treated and control
groups preceding any variation in tumor volume. Therefore,
hemodynamic parameters may provide early monitoring of
treatment efficacy and allow timely changes in treatment plan.
Muir et al40 quantified CBF in C57Bl/6 mice by using a
cardiac spin-labeling technique both in basal conditions and
hypercapnia by placing the labeling coil in the heart instead of
the neck, to avoid signal-intensity saturation. Animals were
imaged with a head coil and a circular labeling coil at the heart
position, in parallel and 2 cm apart. A GRE EPI sequence was
used tomeasure absolute CBF values that were cross-validated
through the use of microspheres, iodoantipyrine autoradiog-
raphy, and laser speckle flowmetry.
Diffusion MR Imaging
DWI is sensitive to tissue structure at the cellular level, reflect-
ing the dynamics of water molecules in the microscopic envi-
ronment. Water diffusion inside a tumor is heterogeneous,
accounting for regional differences in cellular density mainly
due to tumor necrosis and apoptosis. This spatial heterogene-
ity can be easily depicted on ADC maps and histograms and
may reflect regional differences in treatment response (Fig
7).44Whereas a histogram shift to higher ADCvalues indicates
a good response, a shift to lower values indicates poor or no
response and precedes changes in tumor volume, allowing
early assessment of treatment effectiveness. With high-field
scanners, often used to image small animals, spin-echo-based
DWI sequences have higher quality than EPI-based sequences
because they are less prone to susceptibility artifacts. In most
animal-dedicated scanners, high-resolution DWI data can be
obtained within a reasonable timeframe by using spin-echo
multisection sequences, isotropic diffusion, flow compensa-
tion, first-moment motion, and navigator echo correction.
Until currently, most DWI studies were performed on rat
models and only a few in mice (On-line Table 3).44-47
In a study by Moffat et al,44 DWI was used to evaluate
treatment response to low and high doses of carmustine in a
rat model of HGG. Parametric ADC maps and histograms
predicted treatment response before any changes in tumor
volume could be depicted. This early information can replace
traditional therapeutic end points, allows timely secondary in-
terventions, and, on clinical grounds, prevents the morbidity
and cost of pursuing inefficient therapies.
Chenevert et al45 validated DWI as a surrogate marker of
cell density after treatment with carmustine in a 9L rat model
ofHGG. Isotropic ADCmaps andADCpixel value histograms
were obtained from whole tumor by manual delineation. Se-
rial posttreatment ADC histograms showed increased diffu-
32 Borges  AJNR 33  Jan 2012  www.ajnr.org
sion peaking at day 8 after treatment, before any volume
changes could be noted, and they correlated well with the
course of cellular density over time, quantitatively assessed on
histology.
The DWI features of the U87MG mouse xenograft were
characterized by Sun et al46 by using a spin-echo DWI se-
quence with 2 b-values (100 and 750 mm2/s). Radial assess-
ment of mean ADC values from the tumor core to tumor
periphery and surrounding normal-appearing brain were ob-
tained, demonstrating regional differences within the tumor.
Fan et al47 correlated DWI and PWI parameters with cel-
lular attenuation and MVD respectively, on a rat model of C6
HGG. These authors used an EPI-DWI sequence with 2 b-val-
ues (0 and 1000mm2/s) on a 1.5T clinical scanner. ADC values
averaged from 3 to 5 different ROIs were compared with his-
tologic assessment of cell density. A gradual decrease of mean
ADC values was seen during a 4-week period, but correlation
with cellular density was only moderate (r  0.682) in this
study. The authors found, however, that peritumoral ADC
values could be used to discriminate tumor infiltration from
edema.
Hypoxia Imaging (BOLD, T2*-Weighted)
Tumor oxygenation is of utmost importance because oxygen
regulates gene expression through the activation and inhibi-
tion of several transcription factors controlling genetic mod-
ules of angiogenesis, metabolism, migration, invasion, and
proliferation.48 It has long been recognized that the oxygen-
ation status of a tumor predicts its response to radiation ther-
apy and correlates with regional tumor control.49 Therefore,
noninvasive determination of regional hypoxic fractions of a
tumor became a major imaging goal. This information can be
used to identify patients most likely to benefit from radiosen-
sitizers and hypoxia selective drugs.49
The criterion standard method to evaluate tumor oxygen-
ation is the use of polarographic oxygen microelectrodes in-
troduced within the tumor. Besides being invasive, this tech-
nique measures the oxygen tension in limited areas of the
tumor and does not account for regional heterogeneity.
Several imaging techniques have attempted to measure tu-
mor hypoxia either directly or indirectly. The most promising
has been PET imaging by using the 18fluorine 18–labeledmis-
onidazole radiotracer or under 15O inhalation. Nevertheless,
fluorine 18–labeled misonidazole shows significant binding
only when oxygen tension is very low.
1H and 31P MR spectroscopy provide indirect measures of
oxygen tension by evaluating lactate/creatine, monoester/
ATP, and inorganic phosphorous/ATP ratios, respectively,
which reflect the rate of anaerobic glycolysis under hypoxia:
the lower the oxygen tension, the higher these ratios.
PWI, by providing information onMVD and vascular per-
meability, can also be regarded as an indirect measure of the
hypoxic fraction of a tumor, though it does not account for
either the rate of oxygen extraction or for nonfunctional mi-
crovessels that do not participate in effective tumor perfusion.
Another promising MR imaging technique is the use of
BOLD (T2*-weighted) imaging. T2* is modified by small dif-
ferences in oxygen blood saturation through the paramagnetic
effect of deoxyhemoglobin. Although the BOLD effect is also
influenced by blood flow and blood volume, Goldbrunner et
al35 demonstrated the presence of perfusion/oxygenationmis-
matches by using both techniques (rCBF/T2*).
Applications in Preclinical Trials
Robust model systems are mandatory for an efficient and
rapid screening of drugs or combinations of drugs that target
specific oncogenic pathways. In fact, the quality of preclinical
trials depends on appropriate model selection and on the
identification of relevant biomarkers of drug efficacy.2,3,5,7
Whereas in vitro systems, by using cell lines, are easier to con-
Fig 7. ADC imaging. A, Delineation of the ROI (left, green limits), intensity versus b value graph of a representative pixel (right), and a parametric color-coded map (center). Serial histograms
over time on the second week (B) and on the third week (C) after tumor implantation depict a progressive leftward shift reflecting a decrease in ADC values secondary to increased tumor
growth and cellularity.
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trol, only in vivo systems can adequately recapitulate the cel-
lular heterogeneity of tumors and the complexity of tumor-
host interactions.
The ideal mouse model for drug development should
provide a faithful recapitulation of the genetic and molec-
ular features of the native tumor, be easy to use, have a high
penetrance and a short and predictable latency, and allow
timely evaluation of treatment effect (On-line Table
4).1,3,19,32,39,44,45,50-56
It is not unusual that drugs that appear very promising in
preclinical trials have disappointing clinical results.2,14 A re-
cent review by Amarasingh et al51 assessed the impact of che-
motherapy drug research in neuro-oncology. These authors
performed a stratified meta-analysis on the efficacy of nitro-
sureas (carmustine and lomustine) in animal models of HGG
to generate global efficacy estimates. Problems weremanifold:
Most studies enrolled a limited number of animals and meth-
odologies varied widely from one study to another in terms of
animalmodel, treatment timing, dose scheduling, and admin-
istration route, disturbing global analyses. Several biases in
animal experiments, including randomization, allocation,
concealment, and outcome assessment, may be responsible
for the overall increased efficacy of drugs in animal studies.
Other shortcomings included neuropathologic differences
with human neoplasm and a wide variation in the biologic
behavior and genetic profiling of different glioma cell lines.
Many studies assessed the efficacy of antiangiogenic agents
in animal models of HGG.19,39,44-46,51-56 Moffat et al52 com-
pared tumor growth, perfusion parameters, and chemother-
apy effectiveness in wild type, VEGF-A overexpressing, and
VEGF-A underexpressing 9L gliosarcoma rat xenografts. Per-
fusion parameters, CBV and CBF, were quantified both by
DSC-PWI and continuous arterial spin-labeling and were
confrontedwithMVDand immunohistochemical and genetic
analysis by real-time quantitative polymerase chain reaction.
Compared with wild type, VEGF-A overexpressing tumors
showed an increased growth rate; a decreased mean survival
time; and an increased CBF, CBV, andMVD. VEGF-A under-
expressing tumors showed a decreased growth rate and an
increased mean survival but increased CBF, CBV, and MVD
due to the compensatory overexpression of VEFG-D. This
study demonstrated that suppression of an angiogenic path-
way can be counteracted by the compensatory overexpression
of another, accounting for the adaptive ability of neoplasms.
Antiangiogenic drugs decrease CBVby suppressing new blood
vessel formation and decreasing vascular permeability, but
they cause a slight increase in CBF due to the normalization of
pre-existing blood vessels, which ameliorates tumor oxygen-
ation and blood delivery to tumor cells, supporting the in-
creased efficacy of cytotoxic therapies. Therefore, CBV and
CBF constitute different and independent biomarkers of per-
fusion, providing complementary information about tumor
vascularization.
De Groot et al19 assessed the imaging and biologic features
of HGG after antiangiogenic treatment with bevacizumab
(monoclonal antibody against VEGF receptor), both in hu-
mans and in a highly angiogenic poorly infiltrative U87mouse
xenograft. After a 4- to 6-week treatment course, MR imaging
showed a shift to a highly infiltrating poorly angiogenic phe-
notype in humans that was accompanied by the overexpres-
sion of insulin growth factor–binding protein 2, membrane-
boundMMP2, carbonic anhydrase 9, and coagulation factor 8
and by tumor resistance to any subsequent treatments. Histo-
logic analysis of human tumor biopsies has shown decreased
MVD, microvessel normalization, and invasion of the neuro-
pil, and that of mice tumors showed very invasive borders,
perivascular and subpial invasion, and recovery of BBB integ-
rity. Genetic analysis underscored insulin growth factor–
binding protein 2 and MMP2 as the main mediators of this
phenotypic shift in tumors evading chronic antiangiogenic
treatment.
To evaluate the impact of bevacizumab on the antitumor
efficacy of temozolomide, Mathieu et al53 treated 4 different
cell lines and a mouse model of HGG with bevacizumab, te-
mozolomide, and the combination of both. The combined
treatment group showed increased survival and an antiangio-
genic effect of temozolomide operating through a mechanism
different from that of bevacizumab (overexpression of galec-
tin 1).
McConville et al54 used the Ntv-a GEMM of HGG to ap-
praise the role of conventional MR imaging and DWI in gli-
oma grading and in early prediction of treatment response to
temozolomide.MR imagingwas able to predict tumor grading
among the heterogeneous group of high- and low-grade glio-
mas generated by this model, treatment response, and sur-
vival. DWI, in particular, was able to monitor therapy-in-
duced cell kill: Changes in net ADC values predicted
volumetric change as early as 4–5 days after the beginning of
treatment.
Breton et al55 monitored the effect of suicide gene therapy
in theU87MGmousemodel by usingmanual segmentation of
T1 and T2 tumor volumes on serial MR imaging studies per-
formed on a low-field 0.1T scanner. The authors determined
tumor doubling times before and after treatment with suicide
genes (injected locally) and the prodrug 5-fluorocytosine,
proving the efficacy of this approach.
The efficacy of an oncolytic viral treatment for HGG by
using glioblastoma multiforme spheroid xenografts orthoto-
pically implanted in rats was assessed by Huszthy et al.56 After
MR imaging identification, tumors were stereotactically in-
jected with the oncolytic vector. Tumor growth was followed
by contrast-enhanced MR imaging and was correlated with
histologic analysis to assess proliferation, apoptosis, angiogen-
esis, and infiltration by inflammatory cells (CD68-positivemi-
croglia). Infected tumors showed a decreased proliferation in-
dex,MVD, and vessel area fraction and an increased apoptosis
and microglia in central tumor areas.
Current Developments/Molecular Imaging
New imaging applications are quickly emerging and are being
applied to animal models, mostly to provide molecular infor-
mation bridging the gap between neuroimaging and neurobi-
ology.57,58 The increasing use of biologic treatment regimens is
driving the need to identify the biologically active target tissue.
Oncogenetic changes serve as specific targets for tailored ther-
apies and can be depicted by noninvasive imaging. Molecular
imaging provides a noninvasive visual representation of bio-
logic processes at the cellular and molecular levels in the 3D
space, without the associated morbidity and time consumed
on tissue sampling.58
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Transfection techniques enable the visualization of trans-
gene expression by coupling, in the same amplicon, 1 or sev-
eral reporter genes that can be visualized by different imaging
techniques with a gene of interest or via promoter-based co-
expression.59 Increased expression of transferring receptor at
the cell membrane increases iron binding 500% after the
administration of iron-based contrast agents.60 This simple
system allows the visualization of cells/tissues expressing this
transgene on MR imaging, through a T2* signal-intensity
drop, which then functions as a surrogate marker of transgene
expression.60
Fluorescent imaging of signaling transduction pathways
has also been achieved. One of the best known systems in
neuro-oncology is the dual reporter gene cis-p53/tirosine ki-
nase- green fluorescent protein, reflecting the transcriptional
activity of the tumor-suppressor gene p53, induced by DNA
damage.
Radiolabeling can also be used to approach transgene ex-
pression and monitor gene therapy by using SPECT or PET.
The most promising radiotracers in neuro-oncology include
fluorine-labeled misonidazole, fluorodeoxythymidine, and
annexin V to image hypoxia, proliferation, and apoptosis, re-
spectively. Under extensive research are the 11C-radiolabeled
antisense oligonucleotide for the visualization of the glial
fibrillary acidic proteinmessenger ribonucleic acid expression
and 123I VEGF to visualize VEGF receptor.59
Near-infrared optic imaging has a vast potential for the
visualization of biologic processes. The main shortcoming is
the narrow penetrance of visible light, limiting its use to su-
perficial neoplasms. In orthotopic models of brain tumors,
near-infrared optic imaging is invasive, requiring a “brain
window” to visualize the emitted light. However, coupledwith
fluorescence tomography, it not only allows the visualization
of deep-seated tumors but also provides spatial localization.
Using diffuse optic tomography and a brain window, Saxena
et al61 identified the hypoxic fraction of a U87MG mouse
model of HGG by using a green fluorescent protein reporter
gene under the hypoxia responsive element promoter.
Tumor metabolomics is another promising research field
in animal models of HGG. Using MR spectroscopy and mass
spectrometry to explore metabolite profiling in brain tumors,
Griffin et al62 found a good correlation between metabolic
phenotypes and tumor type, proliferation index, metabolic
activity, and cell death. Tumormetabolism can be approached
in vivo by using MR spectroscopy (which provides additional
spatial information and a metabolic map of the entire tumor)
or ex vivo in tissue samples by high-resolution magic angle
spin spectroscopy or in solution-state tumor extracts by mass
spectrometry. Currently the use of 1H, 31P, and 13C MR spec-
troscopy pictures a wide range of metabolites belonging to
different classes of compounds. An important application is
the discrimination of cell death mechanisms through meta-
bolic lipid profiling by 1H-MR spectroscopy, whereas the pres-
ence of saturated lipids indicates cell death by necrosis, and
polyunsaturated fatty acids indicate cell death by apoptosis.
13C spectra estimates glycolytic and oxidative metabolism and
can depict metabolic shifts from oxidative to anaerobic and
glucose carbon shunting surgery to anabolic pathways.Hyper-
polarized 13C-containing substrates can be used to monitor
oxidative and anaerobicmetabolism in vivo without the use of
radioactivity, and they are more sensitive than PET.
Multimodality imaging systems provide complementary
information on a single examination. PET/CT already in clin-
ical use and PET-MR imaging, on its way, combinesmolecular
and functional information with high-resolution anatomic
imaging. Trimodal (functional, metabolic, and anatomic) im-
aging data can be integrated to outline tumor target and func-
tional risk areas. Radiolabeled, fluorescent, and paramagnetic
probes can be used together to directly visualize endogenous
proteins by PET, optical imaging, and MR imaging,
respectively.
Outlook
A wide range of research and preclinical therapeutic trials on
neurologic disorders rely on animal, mostly murine, studies.
Progressive refinements of MR imaging hardware and soft-
ware made neuroimaging of small animals, such as mice, in-
creasingly powerful. Currently, all available functional MR
imaging studies can be applied to murines, dramatically im-
proving the value of animal-based preclinical trials and pro-
viding longitudinal noninvasive surrogate markers of biologic
targeted end points for specific drugs. This change led to re-
markable savings both in time and animal burden. Neuroim-
aging research in the areas of molecular imaging and geneti-
cally driven reporter probes is also being increasingly applied
in murines. Major advances in the field of genetic engineering
also led to the emergence of GEMMs, which are now invalu-
able for the understanding of oncogenic pathways driving tu-
mor initiation and maintenance as well as the development of
drugs targeting these pathways. Finally, the possibility of
studying actual patient neoplasms by direct implantation of
tumor explants, spheroids, or derived primary cell line sus-
pensions inmice widens the use of animals to support person-
alized treatment approaches.On these grounds, it is important
that radiologists become aware of this expanding field of re-
search which can determine, in the future, the accurate bio-
logic characterization of individual tumors and the concomi-
tant development of a variety of molecularly targeted and cell-
based therapies.
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